BATcave
BATcave is a clear, evidence-based guide to bipolar androgen therapy across mHSPC, mCRPC, and nonmetastatic prostate cancer.
It brings together the science, the rationale, and the clinical trials in one place so patients and clinicians can quickly understand what BAT is, why it matters, and where it may fit in the future.
Bipolar androgen therapy, usually called BAT, is a treatment strategy in which men remain on medical castration while receiving cyclical high-dose testosterone, creating repeated swings from very high testosterone levels back toward castrate levels over each cycle.
The scientific idea is that prostate cancer cells that have adapted to long periods of androgen deprivation may become vulnerable when they are suddenly exposed to supraphysiologic testosterone and then pushed back into a low-testosterone state.
BAT is still experimental, but it is not a random or purely theoretical idea.
Current evidence comes from a growing body of phase 1 and phase 2 studies, and ongoing trials are now testing BAT not only in metastatic castration-resistant prostate cancer, where most of the clinical experience exists, but also in metastatic hormone-sensitive disease and in nonmetastatic castration-resistant disease.
For patients and clinicians, the main reason BAT has generated interest is that it may do more than simply shrink cancer for a period of time.
Several studies in mCRPC suggest BAT can produce clinical activity, is often reasonably well tolerated in carefully selected men, and may restore sensitivity to androgen receptor targeted drugs after resistance has developed.
That possibility is important because resistance to drugs such as enzalutamide, abiraterone, and darolutamide is one of the central problems in advanced prostate cancer care.
BAT in mCRPC
In metastatic castration-resistant prostate cancer, BAT has been studied most extensively in men with asymptomatic or minimally symptomatic disease who remain fit enough for close monitoring.
The RESTORE program showed that BAT had clinical activity after progression on prior androgen receptor targeted therapy and suggested that rechallenge responses may be stronger after prior enzalutamide than after prior abiraterone.
The broader mCRPC research program has also expanded BAT into rational combinations with immunotherapy, PARP inhibition, chemotherapy, radiation, and biomarker-guided strategies, which shows that the field is moving from feasibility studies toward mechanism-driven trial design.
Among the better known studies in this space are TRANSFORMER, RESTORE, ExBAT, COMBAT-CRPC, and the olaparib plus BAT trial, all of which helped establish BAT as a serious area of investigation rather than a fringe concept.
BAT in mHSPC
In metastatic hormone-sensitive prostate cancer, BAT is being explored earlier in the disease course, before full castration resistance emerges.
Early phase work in hormone-sensitive prostate cancer tested a lead-in with androgen deprivation followed by alternating BAT and androgen deprivation in asymptomatic men with low metastatic burden or nonmetastatic biochemical recurrence, helping establish the idea that BAT might be feasible earlier in treatment.
The ongoing SPIDERMAN trial takes that concept further by enrolling men with mHSPC, starting with ADT plus darolutamide, and then asking whether alternating BAT with darolutamide can delay resistance while also improving fatigue, sexual function, and overall quality of life.
This matters because BAT in mHSPC is not being studied simply as a way to raise testosterone, but as a possible way to reshape tumor adaptation before resistant clones become dominant.
BAT in nmCRPC
In nonmetastatic castration-resistant prostate cancer, the evidence is newer but especially interesting.
The WOMBAT study is the first phase 2 trial specifically designed for men with nmCRPC who have PSA progression on darolutamide, and it is testing whether BAT can prolong metastasis-free survival, extend the useful life of androgen receptor inhibition, and potentially improve health-related quality of life and bone health.
This is an important step because it brings BAT into a disease state where the immediate goal is not only tumor control, but also delaying the transition to visible metastatic disease.
How BAT should be viewed today
BAT should still be considered experimental.
Trials typically exclude men with situations where a burst of testosterone could be unsafe, such as unstable spinal disease, threatening fracture risk, major urinary obstruction, or other disease patterns where short-term tumor stimulation could cause harm before any anticancer effect appears.
That is why BAT should currently be viewed as a clinical-trial strategy or a highly selective specialist approach, rather than a general substitute for standard therapy.
The most balanced way to describe BAT today is that it is an investigational treatment platform with a real biological rationale, credible early and mid-stage clinical data, and multiple active trials trying to define where it fits best.
For some men, especially those with androgen receptor driven disease and limited symptoms, BAT may eventually offer a way to resensitize tumors, improve aspects of quality of life, and create new sequencing options after resistance to standard hormonal therapy.
More information here: https://prostatebat.com/
Bibliography
- SPIDERMAN. ClinicalTrials.gov: NCT07142551
- DaroBAT. EU Clinical Trials: 2025-521051-23-00
- COSMYC. ClinicalTrials.gov: NCT06922318
- APEX. NCI trial listing: NCI-2024-09882
- BAT AR-Sensitivity Study. ClinicalTrials.gov: NCT06305598
- WOMBAT (ANZUP 2201). ClinicalTrials.gov: NCT06594926
- Sipuleucel-T + BAT. ClinicalTrials.gov: NCT06100705
- SPECTRA. ClinicalTrials.gov: NCT06039371
- BAT-RAD. ClinicalTrials.gov: NCT04704505
- ACROBAT. ClinicalTrials.gov: NCT05081193
- VA-BAT. ClinicalTrials.gov: NCT05011383
- STEP-UP. ClinicalTrials.gov: NCT04363164
- PSMA-BAT. ClinicalTrials.gov: NCT04424654
- HI-TECH. ClinicalTrials.gov: NCT03522064
- ExBAT. ClinicalTrials.gov: NCT04558866
- COMBAT-CRPC. ClinicalTrials.gov: NCT03554317
- Olaparib + BAT. ClinicalTrials.gov: NCT03516812
- TRANSFORMER. ClinicalTrials.gov: NCT02286921
- BATMAN. PMC article
- RESTORE. ClinicalTrials.gov: NCT02090114
- Etoposide + BAT Pilot. ClinicalTrials.gov: NCT01084759
- BATTLE / Square-Wave Testosterone. ClinicalTrials.gov: NCT03734653
- High-Dose Exogenous Testosterone Trial. PMC article
- Men’s Cycle Trial. ClinicalTrials.gov: NCT00586898
- Docetaxel + Rapid Androgen Cycling. ClinicalTrials.gov: NCT00587431
- AACR Rapid Androgen Cycling Study. Clinical Cancer Research article